Jesus Maria Hernandez Rivas

List of Publications by Year
in descending order

253 papers	13,430 citations	30070 54 h-index	26613 107 g-index

259 all docs	259 docs citations	259 times ranked	15791 citing authors

#	Article	IF	Citations
1	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	27.8	1,364
2	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 47-52.	21.4	893
3	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	27.8	749
4	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.9	642
5	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
6	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	7.1	488
7	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica, 2010, 95, 589-596.	3.5	240
8	Treatment of High-Risk Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. Journal of Clinical Oncology, 2014, 32, 1595-1604.	1.6	227
9	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	3.5	226
10	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 2010, 24, 629-637.	7.2	188
11	Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÃ¶m's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia, 2007, 21, 541-549.	7.2	187
12	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
13	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia, 2007, 21, 143-150.	7.2	167
14	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia, 2013, 27, 1100-1106.	7.2	167
15	Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome. Blood, 1998, 92, 1735-1742.	1.4	162
16	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood, 2009, 114, 1063-1072.	1.4	152
17	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2014, 28, 823-829.	7.2	148
18	Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica, 2005, 90, 1346-56.	3.5	129

#	Article	IF	Citations
19	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	3.7	126
20	Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5qâ˜ syndrome. Leukemia, 2009, 23, 664-672.	7.2	124
21	Highâ€dose chemotherapy and immunotherapy in adult Burkitt lymphoma. Cancer, 2008, 113, 117-125.	4.1	122
22	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia, 2009, 23, 1515-1527.	7.2	122
23	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	1.6	115
24	The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia, 2008, 22, 1175-1183.	7.2	114
25	Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia, 2011, 25, 110-120.	7.2	113
26	Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. Clinical Cancer Research, 2005, 11, 3661-3667.	7.0	109
27	6q deletion in WaldenstrÃ¶m macroglobulinemia is associated with features of adverse prognosis. British Journal of Haematology, 2007, 136, 80-86.	2.5	109
28	Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Annals of Oncology, 2000, 11, 441-444.	1.2	102
29	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood, 2003, 102, 2994-3002.	1.4	101
30	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia, 2012, 26, 2521-2529.	7.2	100
31	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796.	1.4	97
32	Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood, 2010, 116, 2531-2542.	1.4	96
33	Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. Haematologica, 2018, 103, 148-162.	3.5	96
34	Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood, 2004, 104, 2661-2666.	1.4	92
35	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. American Journal of Pathology, 2001, 158, 1843-1850.	3.8	88
36	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia, 2005, 19, 402-409.	7.2	85

#	Article	IF	Citations
37	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica, 2010, 95, 424-431.	3.5	84
38	Inflammatory Myofibroblastic Tumor of Bone. American Journal of Surgical Pathology, 1997, 21, 1166-1172.	3.7	80
39	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. British Journal of Haematology, 2008, 142, 529-537.	2.5	78
40	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia, 2003, 17, 2016-2024.	7.2	76
41	Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10534-10539.	7.1	73
42	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	2.5	73
43	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451.	2.8	68
44	Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. Blood, 2016, 128, 1282-1289.	1.4	68
45	Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. Journal of Clinical Investigation, 2005, 115, 2351-2362.	8.2	67
46	Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia, 2013, 27, 2393-2396.	7.2	65
47	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	3.5	65
48	Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 2011, 25, 909-920.	7.2	64
49	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. European Journal of Haematology, 2006, 78, 061114074547002-???.	2.2	63
50	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genetics, 2013, 206, 49-62.	0.4	63
51	Doseâ€intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. Cancer, 2013, 119, 1660-1668.	4.1	63
52	Central nervous system recurrence in adult patients with acute lymphoblastic leukemia. Cancer, 2006, 106, 2540-2546.	4.1	60
53	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica, 2009, 94, 364-371.	3.5	59
54	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica, 2011, 96, 238-244.	3.5	57

#	Article	IF	Citations
55	Trisomies 8 and 20 in desmoid tumors. Cancer Genetics and Cytogenetics, 1996, 92, 147-149.	1.0	56
56	Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia, 2005, 19, 713-720.	7.2	55
57	Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry Part B - Clinical Cytometry, 2010, 78B, 154-168.	1.5	53
58	Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. British Journal of Haematology, 1996, 92, 574-581.	2.5	50
59	Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia, 2001, 15, 840-845.	7.2	50
60	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosomeâ€“negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894.	1.4	48
61	Immunophenotypic and Cytogenetic Comparison of WaldenstrÃ¶m's Macroglobulinemia with Splenic Marginal Zone Lymphoma. Clinical Lymphoma and Myeloma, 2005, 5, 241-245.	2.1	47
62	Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin's lymphomas withBCL6/LAZ3 rearrangement. Genes Chromosomes and Cancer, 1995, 14, 1-7.	2.8	46
63	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. British Journal of Cancer, 1993, 68, 1227-1231.	6.4	45
64	Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1448-1456.	3.5	45
65	Highâ€throughput sequencing analysis of the chromosome 7q32 deletion reveals <scp>IRF</scp>5 as a potential tumour suppressor in splenic marginalâ€zone lymphoma. British Journal of Haematology, 2012, 158, 712-726.	2.5	45
66	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	2.8	44
67	Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia, 2005, 19, 1088-1091.	7.2	43
68	Treatment of young patients with <scp>P</scp>hiladelphia chromosomeâ€positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. British Journal of Haematology, 2012, 159, 78-81.	2.5	43
69	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <scp>B</scp> acute lymphoblastic leukemia enrolled in <scp>PETHEMA</scp> protocols. Cancer, 2015, 121, 3809-3817.	4.1	43
70	Design and application of a 23â€gene panel by nextâ€generation sequencing for inherited coagulation bleeding disorders. Haemophilia, 2016, 22, 590-597.	2.1	43
71	Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. Leukemia, 2001, 15, 1475-1484.	7.2	42
72	Incidence and clinical characteristics of myeloproliferative neoplasms displaying a <scp>PDGFRB</scp> rearrangement. European Journal of Haematology, 2012, 89, 37-41.	2.2	42

#	Article	IF	Citations
73	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	12.8	42
74	Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. Oncotarget, 2016, 7, 30492-30503.	1.8	41
75	Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS ONE, 2016, 11, e0148972.	2.5	40
76	Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl. Experimental Cell Research, 2006, 312, 938-948.	2.6	38
77	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2017, 10, 83.	17.0	38
78	Characterization of a recurrent translocation t(2;3)(p15â€“22;q26) occurring in acute myeloid leukaemia. Leukemia, 2006, 20, 48-54.	7.2	37
79	Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14. PLoS ONE, 2012, 7, e48485.	2.5	37
80	Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. BMJ Open, 2016, 6, e011031.	1.9	37
81	Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica, 2002, 87, 154-66.	3.5	37
82	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
83	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. Thrombosis and Haemostasis, 2017, 117, 66-74.	3.4	36
84	Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. Annals of Hematology, 1993, 67, 217-222.	1.8	35
85	Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. The Hematology Journal, 2004, 5, 227-233.	1.4	35
86	New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. Cancers, 2018, 10, 110.	3.7	35
87	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. British Journal of Cancer, 2017, 117, 256-265.	6.4	34
88	Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. British Journal of Haematology, 1991, 79, 408-414.	2.5	33
89	Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood, 2003, 102, 2699-2700.	1.4	33
90	Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. British Journal of Haematology, 2006, 133, 642-645.	2.5	32

#	Article	IF	Citations
91	Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells, Molecules, and Diseases, 2011, 46, 115-118.	1.4	32
92	Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2019, 45, 695-707.	2.7	32
93	geneCBR: a translational tool for multiple-microarray analysis and integrative information retrieval for aiding diagnosis in cancer research. BMC Bioinformatics, 2009, 10, 187.	2.6	31
94	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large Bâ€cell lymphomas. Cancer, 2009, 115, 3728-3737.	4.1	31
95	Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia, 2013, 27, 610-618.	7.2	31
96	DNA copy number profiling reveals different patterns of chromosomal instability within colorectal cancer according to the age of onset. Molecular Carcinogenesis, 2016, 55, 705-716.	2.7	30
97	The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget, 2017, 8, 26027-26040.	1.8	30
98	Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 153, 16-25.	1.0	29
99	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 2011, 96, 468-471.	3.5	29
100	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget, 2016, 7, 80916-80924.	1.8	29
101	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia Research, 2016, 40, 1-9.	0.8	29
102	Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. PLoS ONE, 2016, 11, e0164370.	2.5	28
103	Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer, 2010, 10, 454.	2.6	26
104	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematological Oncology, 2016, 34, 84-92.	1.7	26
105	Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. Platelets, 2018, 29, 192-195.	2.3	26
106	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	2.5	25
107	Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. Oncotarget, 2017, 8, 71234-71248.	1.8	25
108	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	2.5	25

#	Article	IF	Citations
109	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with riskâ€adapted protocols. Cancer, 2014, 120, 3958-3964.	4.1	24
110	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2015, 10, e0143073.	2.5	24
111	Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with nonâ€Hodgkin's lymphoma. British Journal of Clinical Pharmacology, 2016, 82, 1517-1527.	2.4	24
112	Richter transformation driven by Epsteinâ€“Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	4.5	24
113	Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implications for minimal residual disease detection. Human Pathology, 1997, 28, 154-159.	2.0	23
114	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. PLoS ONE, 2011, 6, e24939.	2.5	23
115	Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metabolism and Personalized Therapy, 2016, 31, 25-34.	0.6	23
116	Development of acute leukaemia after idiopathic myelofibrosis.. Journal of Clinical Pathology, 1992, 45, 427-430.	2.0	21
117	Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2015, 10, e0126555.	2.5	21
118	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Annals of Hematology, 2017, 96, 1069-1075.	1.8	21
119	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia, 2020, 34, 1599-1612.	7.2	21
120	Sitosterolemia: Diagnosis, Metabolic and Hematological Abnormalities, Cardiovascular Disease and Management. Current Medicinal Chemistry, 2019, 26, 6766-6775.	2.4	21
121	The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. Haematologica, 2004, 89, 1213-8.	3.5	21
122	Chromosomal imbalances identified by comparative genomic hybridization in sporadic parathyroid adenomas. European Journal of Endocrinology, 2002, 146, 209-213.	3.7	20
123	New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). Leukemia Research, 2008, 32, 727-736.	0.8	20
124	High-resolution genome-wide analysis of chromosomal alterations in elastofibroma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 681-687.	2.8	20
125	The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with doseâ€intensive chemotherapy including rituximab. British Journal of Haematology, 2016, 172, 428-438.	2.5	20
126	Valores de referencia de parÃ¡metros de rigidez arterial y su relaciÃ³n con los factores de riesgo cardiovascular en poblaciÃ³n espaÃ±ola. Estudio EVA. Revista Espanola De Cardiologia, 2020, 73, 43-52.	1.2	20

#	Article	IF	Citations
127	Anomalies of chromosomes 17 and 22 in giant cell fibroblastoma. Cancer Genetics and Cytogenetics, 1997, 97, 165-166.	1.0	19
128	Wiskottâ€“Aldrich syndrome in a child presenting with macrothrombocytopenia. Platelets, 2017, 28, 417-420.	2.3	19
129	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. PLoS ONE, 2019, 14, e0216674.	2.5	19
130	Chronic lymphocytic leukemia patients with <scp>IGH</scp> translocations are characterized by a distinct genetic landscape with prognostic implications. International Journal of Cancer, 2020, 147, 2780-2792.	5.1	19
131	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. BioMed Research International, 2018, 2018, 1-8.	1.9	18
132	Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. Leukemia Research, 2006, 30, 943-948.	0.8	17
133	Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 955-956, 93-97.	2.3	17
134	Analyse multiple disease subtypes and build associated gene networks using genome-wide expression profiles. BMC Genomics, 2015, 16, S3.	2.8	17
135	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 146-154.	1.3	17
136	Response to imatinib mesylate in patients with hypereosinophilic syndrome. International Journal of Hematology, 2012, 96, 320-326.	1.6	16
137	Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Annals of Hematology, 2013, 92, 1543-1552.	1.8	16
138	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â^'7/7qâ^' detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.8	16
139	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	2.6	16
140	ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia. Cells, 2020, 9, 215.	4.1	16
141	Heterogeneity of structural abnormalities in the 7q31.3â^¼q34 region in myeloid malignancies. Cancer Genetics and Cytogenetics, 2004, 150, 136-143.	1.0	15
142	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763.	2.8	15
143	Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome. Genes Chromosomes and Cancer, 2014, 53, 788-797.	2.8	15
144	Identification of expression patterns in the progression of disease stages by integration of transcriptomic data. BMC Bioinformatics, 2016, 17, 432.	2.6	15

#	Article	IF	Citations
145	Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. Leukemia and Lymphoma, 2018, 59, 1095-1104.	1.3	15
146	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia, 2019, 33, 518-558.	7.2	15
147	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. Diagnostics, 2021, 11, 853.	2.6	15
148	del(7q) in chronic B-cell lymphoid malignancies. Cancer Genetics and Cytogenetics, 1997, 93, 147-151.	1.0	14
149	Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL+ and mBCR/ABL+ cases. British Journal of Haematology, 2006, 132, 736-739.	2.5	14
150	Mutation Status and Immunoglobulin Gene Rearrangements in Patients from Northwest and Central Region of Spain with Chronic Lymphocytic Leukemia. BioMed Research International, 2014, 2014, 1-8.	1.9	14
151	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpGâ€stimulated chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 978-983.	4.1	14
152	Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leukemia and Lymphoma, 2016, 57, 86-91.	1.3	14
153	Increased survival due to lower toxicity for highâ€risk Tâ€cell acute lymphoblastic leukemia patients in two consecutive pediatricâ€inspired PETHEMA trials. European Journal of Haematology, 2019, 102, 79-86.	2.2	14
154	Characterization by chromosome painting of balanced and unbalanced x chromosome translocations in myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 1995, 82, 17-22.	1.0	13
155	Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Annals of Oncology, 2012, 23, 2138-2146.	1.2	13
156	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. British Journal of Haematology, 2013, 163, 47-54.	2.5	13
157	Targeted genome editing in acute lymphoblastic leukemia: a review. BMC Biotechnology, 2018, 18, 45.	3.3	13
158	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer, 2019, 125, 2810-2817.	4.1	13
159	A pediatric regimen for adolescents and young adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer Medicine, 2020, 9, 2317-2329.	2.8	13
160	Immunophenotypic characterisation of acute leukaemia after polycythemia vera.. Journal of Clinical Pathology, 1993, 46, 668-671.	2.0	12
161	Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme. Journal of Neuro-Oncology, 2012, 110, 69-77.	2.9	12
162	Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenetics and Genomics, 2012, 22, 381-388.	1.5	12

#	Article	IF	Citations
163	A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples. BMC Genomics, 2014, 15, 879.	2.8	12
164	TET2Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence ofTET2Variations. BioMed Research International, 2014, 2014, 1-6.	1.9	12
165	Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. Haematologica, 2021, 106, 2215-2223.	3.5	12
166	Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. Blood Cancer Journal, 2021, 11, 127.	6.2	12
167	Trisomy/ Tetrasomy of Chromosome 8 and +i(8q) as the Sole Chromosome Abnormality in Three Adult Patients with Myelomonocytic Leukemia. Cancer Genetics and Cytogenetics, 2000, 120, 163-165.	1.0	11
168	Correlation of myelodysplastic syndromes with i(17)(q10) and <scp>TP</scp>53 and <scp>SETBP</scp>1 mutations. British Journal of Haematology, 2015, 171, 137-141.	2.5	11
169	Azacitidine improves outcome in higherâ€risk <scp>MDS</scp> patients with chromosome 7 abnormalities: a retrospective comparison of <scp>GESMD</scp> and <scp>GFM</scp> registries. British Journal of Haematology, 2018, 181, 350-359.	2.5	11
170	Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing. Annals of Medicine, 2019, 51, 141-148.	3.8	11
171	Adverse prognostic impact of complex karyotype (â‰¥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.8	11
172	Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. Oncotarget, 2016, 7, 80664-80679.	1.8	11
173	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Annals of Hematology, 1997, 74, 79-82.	1.8	10
174	Chromosomal abnormalities are related to location and grade of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 982-985.	1.3	10
175	Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag. Platelets, 2020, 31, 993-1000.	2.3	10
176	Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma-derived cell line. Cancer Genetics and Cytogenetics, 2004, 151, 171-177.	1.0	9
177	Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. Cancer Genetics and Cytogenetics, 2005, 160, 68-72.	1.0	9
178	Integration of Global Spectral Karyotyping, CGH Arrays, and Expression Arrays Reveals Important Genes in the Pathogenesis of Glioblastoma Multiforme. Annals of Surgical Oncology, 2012, 19, 2367-2379.	1.5	9
179	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.8	9
180	DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains. Experimental Hematology, 2019, 72, 9-13.	0.4	9

#	Article	IF	Citations
181	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. Annals of Hematology, 2021, 100, 1995-2004.	1.8	9
182	Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences. American Journal of Hematology, 1993, 43, 256-258.	4.1	8
183	Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology and Cell Therapy, 1997, 39, 223-227.	0.7	8
184	Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. Leukemia Research, 2004, 28, 1181-1187.	0.8	8
185	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. Leukemia Research, 2016, 46, 30-36.	0.8	8
186	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 633-642.	1.3	8
187	Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. The Hematology Journal, 2003, 4, 67-70.	1.4	8
188	Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial. Blood, 2020, 136, 28-29.	1.4	8
189	FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5ï¿½Mb included in the minimal region deleted in 1p36 deletion syndrome. Human Genetics, 2005, 116, 476-485.	3.8	7
190	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2009, 50, 571-581.	1.3	7
191	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	2.8	7
192	A rare but recurrent t(8;13)(q24;q14) translocation in Bâ€cell chronic lymphocytic leukaemia causing <scp>MYC</scp> upâ€regulation and concomitant loss of <scp>PVT</scp>1, miRâ€15/16 and <scp>DLEU</scp>7. British Journal of Haematology, 2016, 172, 296-299.	2.5	7
193	Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. Clinical and Translational Medicine, 2021, 11, e304.	4.0	7
194	Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency. Journal of Molecular Diagnostics, 2022, 24, 462-475.	2.8	7
195	Uniparental disomy causes deficiencies of vitamin Kâ€dependent proteins. Journal of Thrombosis and Haemostasis, 2016, 14, 2410-2418.	3.8	6
196	Nuevos mÃ©todos diagnÃ³sticos en los trastornos plaquetarios hereditarios. Medicina ClÃ¬nica, 2017, 148, 71-77.	0.6	6
197	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. American Journal of Hematology, 2017, 92, E534-E541.	4.1	6
198	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	2.8	6

#	Article	IF	Citations
199	The poor prognosis of low hypodiploidy in adults with Bâ€cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	2.5	6
200	Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse. Diagnostics, 2020, 10, 455.	2.6	6
201	In vitro autonomous proliferation in ANLL: Clinical and biological significance. Leukemia Research, 1995, 19, 411-416.	0.8	5
202	Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia, 1998, 12, 1497-1499.	7.2	5
203	Cell Cycle Analysis of WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 250-252.	2.1	5
204	Analysis of chromosomal imbalances in an elderly woman with a giant cell tumour. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 95-99.	2.8	5
205	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2015, 56, 2812-2818.	1.3	5
206	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. Annals of Hematology, 2016, 95, 719-732.	1.8	5
207	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2318-2326.	1.3	5
208	Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. Trials, 2020, 21, 437.	1.6	5
209	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e513-e522.	0.4	5
210	Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome. Blood, 1998, 92, 1735-1742.	1.4	5
211	Translocation(15;17)(q22;q21) in a patient with Klinefelter syndrome. Cancer Genetics and Cytogenetics, 1996, 86, 86.	1.0	4
212	Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders. Annals of Hematology, 1997, 74, 209-214.	1.8	4
213	Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation. Leukemia Research, 2011, 35, 1188-1192.	0.8	4
214	A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leukemia Research, 2017, 56, 82-87.	0.8	4
215	Hyperdiploidy as a rare event that accompanies poor prognosis markers in <scp>CLL</scp>. European Journal of Haematology, 2017, 98, 142-148.	2.2	4
216	1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia. Clinical and Experimental Medicine, 2019, 19, 261-267.	3.6	4

#	Article	IF	Citations
217	Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients. Journal of Personalized Medicine, 2020, 10, 137.	2.5	4
218	Cytogenetic and genomic analysis of a patient with turner syndrome and t(2;12): a case report. Molecular Cytogenetics, 2020, 13, 46.	0.9	4
219	Continuous oral cytarabine ocfosfate with interferon-Î±-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study. British Journal of Haematology, 2001, 115, 541-544.	2.5	3
220	Alteration in Endoglin-Related Angiogenesis in Refractory Cytopenia with Multilineage Dysplasia. PLoS ONE, 2013, 8, e53624.	2.5	3
221	Machine learning applied to gene expression analysis of T-lymphocytes in patients with cGVHD. Bone Marrow Transplantation, 2020, 55, 1668-1670.	2.4	3
222	Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. Pharmacogenomics Journal, 2020, 20, 664-671.	2.0	3
223	Rearrangements of ATP5Lâ€KMT2A in acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 192, e139-e144.	2.5	3
224	CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia. CRISPR Journal, 2021, 4, 519-535.	2.9	3
225	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. Blood, 2006, 108, 103-103.	1.4	3
226	TRAF3 alterations are frequent in delâ€3â€²<scp>IGH</scp> chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. American Journal of Hematology, 2022, 97, 903-914.	4.1	3
227	CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML. International Journal of Molecular Sciences, 2022, 23, 6386.	4.1	3
228	Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. Leukemia Research, 2009, 33, 170-173.	0.8	2
229	Automatic knowledge extraction in sequencing analysis with multiagent system and grid computing. Journal of Integrative Bioinformatics, 2012, 9, 93-104.	1.5	2
230	A Modern Approach to the Molecular Diagnosis of Inherited Bleeding Disorders. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2018, 12, .	0.1	2
231	Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. Annals of Hematology, 2019, 98, 2151-2162.	1.8	2
232	Clinical, cytogenetic, and molecular findings in a patient with ring chromosome 4: case report and literature review. BMC Medical Genomics, 2019, 12, 167.	1.5	2
233	NEMHESYSâ€"European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics. HemaSphere, 2021, 5, e541.	2.7	2
234	A novel genetic variant in <scp>PTGS1</scp> affects Nâ€glycosylation of cyclooxygenaseâ€1 causing a dominantâ€negative effect on platelet function and bleeding diathesis. American Journal of Hematology, 2021, 96, E83-E88.	4.1	2

#	Article	IF	Citations
235	Epigenetic Silencing of BIM Mediates Chemotherapy Resistance of Patients with Burkitt Lymphoma That Can Be Overcome by Therapeutic Reactivation of BIM in Mouse and Human Lymphoma Models. Blood, 2008, 112, 607-607.	1.4	2
236	Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenstrol̀ˆmâ€™s Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.. Blood, 2005, 106, 503-503.	1.4	2
237	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leukemia and Lymphoma, 2022, 63, 1993-1996.	1.3	2
238	Automatic knowledge extraction in sequencing analysis with multiagent system and grid computing. Journal of Integrative Bioinformatics, 2012, 9, 206.	1.5	2
239	Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response. Cancer Genetics and Cytogenetics, 2008, 186, 125-126.	1.0	1
240	Clinical Applications of BAC Array-CGH to the Study of Diffuse Large B-Cell Lymphomas. Methods in Molecular Biology, 2013, 973, 121-145.	0.9	1
241	Genomic analysis of clonal eosinophils by <scp>CGH</scp> arrays reveals new genetic regions involved in chronic eosinophilia. European Journal of Haematology, 2014, 93, 422-428.	2.2	1
242	Fluorescencein situhybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2015, 56, 242-243.	1.3	1
243	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1
244	Vascular target organ damage in patients with Philadelphia negative myeloproliferative syndrome: A propensity score analysis. Medicina ClÃnica, 2021, , .	0.6	1
245	GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.. Blood, 2005, 106, 2378-2378.	1.4	1
246	Secondary myeloid neoplasias. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 403-404.	0.7	1
247	Copy number alterations in adult patients with mature B acute lymphoblastic leukemia treated with specific immunochemotherapy. Medicina ClÃnica (English Edition), 2016, 147, 488-491.	0.2	0
248	SAMasGC: Sequencing Analysis with a Multiagent System and Grid Computing. Advances in Intelligent and Soft Computing, 2012, , 209-216.	0.2	0
249	Visual Analysis Tool in Comparative Genomics. Advances in Intelligent and Soft Computing, 2012, , 121-127.	0.2	0
250	Comparative Genomics with Multi-agent Systems. Advances in Intelligent Systems and Computing, 2013, , 175-181.	0.6	0
251	Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia. Blood, 2018, 132, 3082-3082.	1.4	0
252	Identification By Whole Exome Sequencing of the Molecular Defect in a Novel Gene Related to Glycosylation in Two Unrelated Families with Syndromic Macrothrombocytopenia. Blood, 2021, 138, 588-588.	1.4	0

#	Article	IF	Citations
253	Biological Impact of Monoallelic and Biallelic BIRC3 Loss in Del(11q) Chronic Lymphocytic Leukemia Progression. Blood, 2020, 136, 4-4.	1.4	0